Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cyto Pulse Sciences, Inc.
Cyto Pulse, the Karolinska Institute and Uppsala University Hospital Receive Approval from the Swedish Medical Products Agency to Start a Clinical Trial Using a Xenogenic PSA DNA Vaccine
October 29th, 2008
Cyto Pulse Sciences, a leading producer of electric field based, intradermal DNA Vaccine delivery systems, announced approval by Swedish regulatory authorities to begin a Phase I/II study of DNA vaccination in patients with recurring prostate cancer. The trial will investigate the safety of a xenogenic DNA vaccine delivered by the Derma Vax(TM) intradermal electroporation system. The vaccine, which encodes Prostate Specific Antigen (PSA) from a Rhesus Macaque, was developed jointly by Cyto Pulse and the Karolinska Institute and has been licensed to Cyto Pulse. The clinical trial will be conducted at the Department of Oncology at Uppsala University Hospital. Principal...
Source: Vaccine Weekly (2008-10-29)
|
